Initial water weight loss occurs first, followed by steady fat reduction
Currently, NS-2330 is in Phase II clinical trials for AD and undergoing a Phase II tolerability trial for PD patients with dyskinesia
Understanding these differences is vital for tailoring treatment plans to effectively manage diabetes and optimize patient outcomes
Real-world use introduces broader populations, comorbidities, and long-term exposure, making continuous safety monitoring essential
Water intake also supports normal metabolic and digestive processes
Rybelsus addresses this by combining oral semaglutide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, or SNAC, that enables a small fraction of the molecule to reach systemic circulation